ATLANTA — In this video, Infectious Disease News Editorial Board member Ellie J.C. Goldstein, MD, discusses an analysis of nearly 700 Candida auris isolates from New York City, which has experienced more cases of the fungal infection than any other state. None of the isolates included in the study were resistant to all three classes of antifungals, and few showed resistance to echinocandins, which are recommended by the CDC as initial therapy to treat C. auris infections.
Goldstein, a clinical professor of medicine at the University of California, Los Angeles School of Medicine, and director of the R.M. Alden Research Laboratory in Santa Monica, California, said the findings will help guide physicians “with empirical as well as specific therapy.”
O’Brien B. Abstract AAR LB14. Presented at: ASM Microbe; June 7-11, 2018; Atlanta.
Disclosure: Goldstein serves on advisory boards for Bio-K+, Daiichi Sankyo, Merck, Novartis, Paratek Pharmaceuticals, Sanofi-Aventis, Shionogi and Summit Corp., speakers bureaus for Allergan, Bayer, The Medicines Company and Merck, and has received research grants from numerous pharmaceutical companies.